Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Receivables: 2020-2022

Historic Receivables for Tango Therapeutics (TNGX) over the last 1 years, with Dec 2022 value amounting to $2.0 million.

  • Tango Therapeutics' Receivables changed negligibly% to $2.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was $8.0 million, marking a year-over-year change of. This contributed to the annual value of $2.0 million for FY2022, which is negligibly% changed negligibly from last year.
  • Latest data reveals that Tango Therapeutics reported Receivables of $2.0 million as of Q4 2022, which was down 0.00% from $2.0 million recorded in Q3 2022.
  • Tango Therapeutics' Receivables' 5-year high stood at $8.0 million during Q3 2021, with a 5-year trough of $2.0 million in Q4 2020.
  • Moreover, its 3-year median value for Receivables was $2.0 million (2022), whereas its average is $2.9 million.
  • Data for Tango Therapeutics' Receivables shows a maximum YoY crashed of 75.00% (in 2022) over the last 5 years.
  • Over the past 3 years, Tango Therapeutics' Receivables (Quarterly) stood at $2.0 million in 2020, then remained steady at $2.0 million in 2021, then remained steady at $2.0 million in 2022.
  • Its Receivables stands at $2.0 million for Q4 2022, versus $2.0 million for Q3 2022 and $2.0 million for Q2 2022.